Influenza A virus, live attenuated
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2011
- First approval year
- 2011
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Influenza A virus, live attenuated
- influenza a virus live attenuated component of fluenz
- influenza a virus live attenuated component of fluenz tetra
- Influenza a virus, live attenuated component of fluenz
- Influenza a virus, live attenuated component of fluenz tetra
- Pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)
- pandemic influenza vaccine h5n1 astrazeneca previously pandemic influenza vaccine h5n1 medimmune
- influenza a virus live attenuated
- Influenza a virus, live attenuated
- ChEMBL ID
- CHEMBL6068369
- First in class
- No
- Orphan designation
- No
- Drug name stem
- vir-
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Influenza, Human
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
- Condition identifier
- EFO_0007328
- Condition identifier
- MONDO_0005812
- Highest recorded phase
- 4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (53)
- A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study
- A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).
- A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV
- A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
- A Study of Influenza Virus Vaccines in Children and Adults
- B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
- B-cell Immunity to Influenza (SLVP017)- Year 1, 2009
- Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression
- Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
- Exploring Novel Mechanisms of Vaccine Failure LAIV Pilot Study
- FLU-VACS Comparative Study in Adults
- FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care
- FluMist in Egg Allergic Patients
- Gene Signatures of Influenza Vaccine Responses in Older Adults
- GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE
- High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
- High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients